Beljanski Protocol / Beljanski Extracts

The Beljanski Protocol / Beljanski Extracts entry collects the cancer-related system associated with Mirko Beljanski, PhD, and later promoted, researched, and preserved through The Beljanski Foundation, Sylvie Beljanski, and Maison Beljanski. The core cancer-facing ingredients usually discussed under this umbrella are Pao Pereira/Pau Pereira, Rauwolfia vomitoria/Rauvolfia vomitoria, RNA fragments, Ginkgo biloba, and selected green tea blends.

Beljanski's central idea was that cancer DNA is not only genetically mutated, but physically or secondarily destabilized, with the double helix opened over larger areas than normal DNA. The Beljanski Foundation states that Pao Pereira and Rauwolfia vomitoria extracts were selected because they were believed to bind destabilized cancer DNA, slow DNA synthesis, and trigger cancer-cell death while sparing normal cells. That mechanism should be documented as a Beljanski/Foundation claim and research hypothesis, not as settled oncology consensus.

Core Components

• Pao Pereira / Pau Pereira / PB-100: An extract from Geissospermum vellosii. Beljanski-related sources describe it as a flavopereirine-rich or beta-carboline alkaloid-enriched extract with selective anticancer activity in laboratory and animal studies.
• Rauwolfia vomitoria / Rauvolfia vomitoria: A root-bark extract described by Beljanski sources as standardized in alstonine and prepared without reserpine. Foundation material highlights prostate, ovarian, pancreatic, and cancer stem-cell research claims.
• RNA fragments: Small RNA oligonucleotide preparations promoted for bone marrow support, white blood cells, platelets, and recovery from chemotherapy- or radiation-associated immune suppression.
• Ginkgo biloba: Discussed in the Beljanski system mainly as support during radiation and chemotherapy, including claims around nuclease regulation, chromosomal protection, liver support, and radiation side-effect mitigation.
• Green teas / OnkoTea: Tea blends promoted by the Beljanski community for immune and anticancer support, with cited laboratory comparisons against selected cancer cell lines.

Evidence Map

The strongest independent-looking cancer data found in this pass is preclinical. A 2014 Pharm Biol paper by Jun Yu and Qi Chen reported that a Pao Pereira extract inhibited ovarian cancer cell models and potentiated carboplatin in cell and mouse models. A 2009 J Soc Integr Oncol paper reported prostate cancer cell and xenograft findings for Pao Pereira, while also noting a U-shaped dose-response pattern and a potentially narrow dose range. Memorial Sloan Kettering's herb review summarizes Pao Pereira as having preclinical anticancer signals but states that human cancer studies have not been conducted and that safety and effectiveness have not been determined in humans.

The Beljanski Foundation highlights additional foundation-sponsored or foundation-associated research around prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, melanoma, cancer stem cells, BPH, chemotherapy synergy, and immune support. Those links are useful for tracking the claims and research network, but they should be distinguished from conventional clinical proof.

Cancer Contexts

Most disease-specific links are to prostate, ovarian, pancreatic, breast, and melanoma/skin cancer content. The prostate and ovarian links have named preclinical publications. Pancreatic, breast, melanoma, and cancer stem-cell connections are more heavily represented through Beljanski Foundation pages and laboratory-oriented claims.

Controversy and Caution

Beljanski's work sits in a disputed alternative/integrative oncology zone. Supporters frame it as suppressed, natural, non-toxic cancer research; critics and mainstream oncology sources treat the extracts as unproven cancer treatments. The database placement at WooWoo scale 8, Unapproved, reflects this mix: there are identifiable people, organizations, papers, and mechanisms to track, but no established human clinical evidence sufficient to treat it as standard cancer care.

Patients should not use Beljanski extracts as substitutes for oncology treatment. Because these are biologically active botanical or nucleic-acid-related products and may be combined with chemotherapy or radiation in real-world use, they should be reviewed with oncology and pharmacy professionals for interactions, timing, blood counts, liver/kidney issues, and treatment goals.

Key Sources Checked

Sources used for this entry include The Beljanski Foundation pages on Mirko Beljanski, Beljanski and cancer, Pao Pereira, Rauwolfia vomitoria, RNA fragments, and Beljanski extracts; Memorial Sloan Kettering's Pao Pereira herb monograph; PubMed records for the 2014 ovarian cancer Pao Pereira/carboplatin paper and the 2009 prostate cancer Pao Pereira paper; and The Beljanski Cancer Talk Show/podcast page.